For a rare-disease developer that spent years building toward a pivotal readout, 2026 has been a story of expectations meeting hard data. Mereo BioPharma Group plc (NASDAQ:MREO) heads into the autumn under pressure, its shares soft as investors digest a Phase 3 program that …
● The roughly 10% single-session decline is the immediate hook, but no single, clearly identifiable public catalyst explains that specific move.
● That restraint is appropriate: while the September 9 disclosure is the company's most recent development, a small daily move cannot be definitively attributed to any single event.
● MaxCyte has built aBusinessmost investors never see directly: it supplies the cell-engineering technology that helps biotech companies develop cell and gene therapies.
Myriad Genetics has become one of 2026's more closely tracked diagnostics turnaround stories, and not for flattering reasons. After a steep share-price decline and a wave of analyst downgrades, the molecular-diagnostics veteran enters the autumn trading near multi-year lows, with investors focused squarely on …
● Based in Danbury, Connecticut, MannKind develops treatments for endocrine and orphan lung diseases built on its proprietary Technosphere dry-powder inhalation platform.
● Modular Medical develops the Pivot tubeless insulin patch pump, a wearable system that delivers continuous basal and bolus insulin over a three-day wear period, with a removable reservoir, a disposable battery and smartphone connectivity.
Medtronic plc (NYSE:MDT) heads into the back half of 2026 looking less like a name in transition and more like one quietly regaining its footing. A raised fiscal 2027 outlook, delivered alongside a roughly $700 million robotics partnership, gave investors two fresh reasons to …
● MediWound has spent 2026 building a quietly compelling case as a specialist in tissue repair and wound care, and its Nasdaq-listed shares reflect that trajectory near $14 with a marketCapitalizationaround $180 million.
A commercial-stage diagnostics company can post double-digit revenue growth and still find its shares under a dollar, a tension that defines MDxHealth SA (NASDAQ: MDXH) heading into autumn 2026. The Nasdaq-listed molecular diagnostics group has built a growing prostate-cancer testing franchise, yet a sliding …